## Advances in Brief

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>3165</td>
<td>Grb10: A New Substrate of the Insulin-like Growth Factor I Receptor</td>
<td>Andrea Morrione, Barbara Valentinis, Shiwei Li, James Y. T. Ooi, Ben Margolis, and Renato Busegna</td>
</tr>
<tr>
<td>3168</td>
<td>BRCA1 Is a 220-kDa Nuclear Phosphoprotein That Is Expressed and Phosphorylated in a Cell Cycle-dependent Manner</td>
<td>Yumay Chen, Andrew A. Farmer, Chi-Fen Chen, Diane C. Jones, Phang-Lang Chen, and Wen-Hwa Lee</td>
</tr>
<tr>
<td>3173</td>
<td>The FHIT Gene at 3p14.2 Is Abnormal in Breast Carcinomas</td>
<td>Massimo Negri, Carmen Monaco, Igor Vorechovsky, Masataka Ohita, Teresa Druck, Raffaele Baffa, Kay Huebner, and Carlo M. Croce</td>
</tr>
</tbody>
</table>

## Symposia

- Animal Models for Human Cancer: Recent Developments, New Special Lecture (James D. Watson)
- Advances in Chemoprevention (Raymond N. DuBois)
- Genomics, Genetics, and New Approaches to Cancer (Richard D. Ebstein)
- Ubiquitin and Protein Degradation (Alexander J. Varshavsky)
- Infectious Agents and Cancer (Nancy E. Mueller)
- Transcriptional Regulation and Cancer (Lorraine J. Gudas)
- Drug Discovery: From Basic Science to the Clinic (Daniel D. Von Hoff)
- DNA Repair (Richard D. Kolodner)
- Telomeres, Centromeres, and Chromosomal Instability (Carol W. Greider)
- Apoptosis (Craig B. Thompson)
- Molecular Targeted Therapy (John Mendelsohn)
- Gene-Environment Interactions in Cancer Etiology (Margaret R. Spitz)
- Basic and Clinical Approaches to Ovarian Cancer (Robert C. Bast, Jr.)
- Basic and Clinical Approaches to Lung Cancer (David Paul Carbone)
- Diet and Cancer: Process and Paradox (John D. Potter)
- Genetic Instability, DNA Damage, and Checkpoint Regulation (Geoffrey Wahl)
- Topoisomerases in Carcinogenesis and Cancer Treatment (Leroy F. Liu)
- Hormonally Related Tumors - Basic and Clinical Aspects (Bert W. Giordano)
- Drug Resistance and Cell Cycle Abnormalities (Joseph R. Bertino)
- Invasion, Metastasis, and Angiogenesis (Isaiah J. Fidler)
- Advances in Stem Cell Gene Therapy (Cynthia E. Dunbar)
- Replication and the Cell Cycle (Jacqueline A. Lees)
- Tamoxifen: Risks and Benefits
- Future Directions in Research on Tobacco and Cancer (Virginia L. Joseph F. Fraumeni, Jr., Co-Chairperson)

## Carcinogenesis

- Inducible Nitric Oxide Synthase, Nitrotyrosine, and Apoptosis in Helicobacter pylori Gastritis: Effect of Antibiotics and Antioxidants (Elizabeth E. Mannick, Luis E. Bravo, Guillermo Zarama, J. Luis Reaple, Xiao-Jing Zhang, Bernardo Ruiz, Elizabeth T. Fontham, Robertino Mera, Mark J. S. Miller, and Pelayo Correa)
- Targeted Expression of Human O6-Methylguanine-DNA Methyltransferase (MGMT) in Transgenic Mice Protects against Tumor Initiation in Two-Stage Skin Carcinogenesis (Klaus Becker, Jörg Dosch, Cornelia M. Gregel, Brian A. Martin, and Bernd Kaina)
- GADD153/CHOP, a DNA Damage-inducible Protein, Reduced CAAT/Enhancer Binding Protein Activities and Increased Apoptosis in 32D cl3 Myeloid Cells (Alan D. Friedman)
- Growth Regulation by Peroxisome Proliferators: Opposing Activities in Early and Late G1, Brian J. Ledwith, Timothy E. Johnson, Linda K. Wagner, Cindy J. Pauley, Sujata Manam, Sheila M. Galloway, and Warren W. Nichols
- Regulation of Ornithine Decarboxylase in a Transformed Cell Line That Overexpresses Translation Initiation Factor eIF-4E (Lisa M. Shantz, Rei-Huang Hu, and Anthony E. Pegg)
- Calcium in Milk Products Precipitates Intestinal Fatty Acids and Secondary Bile Acids and Thus Inhibits Colonic Cytotoxicity in Humans (Mirjam J. A. P. Govers, Denise S. M. L. Tertorm, John A. Lapet, Jan H. Kleibekker, Roel J. Vonk, and Roelof Van der Meer)

## Endocrinology

- Glucocorticoid Receptor Structure and Function in Glucocorticoid-resistant Small Cell Lung Carcinoma Cells (David W. Ray, Julian R. E. Davis, Anne White, and Adrian J. L. Clark)

## Experimental Therapeutics

- Potentiation of Photodynamic Therapy-elicited Antitumor Response by Localized Treatment with Granulocyte-Macrophage Colony-stimulating Factor (Gorazd Krosig, Mladen Korbelik, Jana Krosig, and Graeme J. Douggherty)
Characterization of angiogenic activity is measured by comparing the ratio of angiogenic stimulators (e.g. VEGF or bFGF) to angiogenic inhibitors (e.g. Endostatin). Applications include: cancer, cardiovascular disease, rheumatoid arthritis, transplant technology and acute phase responses.

ACCUCYTETM: The Accepted Standard for Measuring Angiogenic Signaling

Endogenous levels of angiogenic stimulators and inhibitors

See www.cytimmune.com for additional information.

ENDOSTATI 1.4TM A New Assay for Angiogenesis Research

Measure the Balance...
56 (14)


Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/56/14.citation

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.